DiaCarta Revenue and Competitors

Claim your profile

Location

$53M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • DiaCarta's estimated annual revenue is currently $4.7M per year.(i)
  • DiaCarta received $45.0M in venture funding in February 2018.
  • DiaCarta's estimated revenue per employee is $77,500
  • DiaCarta's total funding is $53M.

Employee Data

  • DiaCarta has 61 Employees.(i)
  • DiaCarta grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. To learn more, visit http://www.diacarta.com.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

$53M

Total Funding

61

Number of Employees

$4.7M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

DiaCarta News

2022-04-20 - Global T-Cell Therapy Market Scope And Forecast | AbbVie ...

Amgen; Bluebird Bio; Celgene Corporation; Cellectis; DiaCarta; Fate Therapeutics; Gilead Sciences; Juno Therapeutics; Kite Pharma; Merck; Novartis; Pfizer...

2022-03-30 - DiaCarta Expands Board Leadership with Industry Veteran

PLEASANTON, Calif. , April 7, 2022 /PRNewswire/ -- DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel...

2022-03-22 - Developing Novel Liquid Biopsy Oncology Tests

AZ: DiaCarta is a molecular diagnostics company borne out of decades of research in next-generation sequencing (NGS), circulating cell-free DNA...

2019-01-17 - CIO Bulletin Announces DiaCarta Inc. As One of the 30 ...

RICHMOND, Calif.--(BUSINESS WIRE)--DiaCarta today announced that CIO Bulletin has named it among the 30 Fastest Growing Companies ...

2018-10-15 - DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue ...

BUSINESS WIRE)--DIACARTA, Inc., a precision diagnostic company and leading developer of products for nucleic acid-based detection ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.2M61-3%N/A
#2
$8M6139%N/A
#3
$8.9M61-10%N/A
#4
$3.5M61-3%N/A
#5
$7.2M615%N/A

DiaCarta Funding

DateAmountRoundLead InvestorsReference
2015-01-12$8.0MABVCFArticle
2018-02-13$45.0MBFortune Fountain CapitalArticle